Organization (Industry)
DR REDDYS LABORATORIES LTD
ClinicalTrials.gov lists DR REDDYS LABORATORIES LTD as lead sponsor of 227 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 more sections with rows · 12 sections measured, none recorded
Logo The Hindu Business Line, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers DR REDDYS LABORATORIES LTD and 1 company grouped under it: 227 lead-sponsored trials (1 its own, 226 in the grouped companies) and 11 legal-entity registrations (1 its own, 10 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| DR. REDDY'S LABORATORIES LIMITED | 226 | 10 |
Disease areas (4)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Carcinoma, Ovarian Epithelial | 1 |
| Ovarian Neoplasms | 1 |
| Papillomavirus Infections | 1 |
| Warts | 1 |
Trials by start year as sponsor or collaborator (2)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2016 | 1 |
No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Journals published in (1)
| Journal | Publications |
|---|---|
| Frontiers in immunology | 1 |
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 3,811,000,000 | 671,000,000 | 320,000,000 |
| 2024 | 3,350,000,000 | 668,000,000 | 274,000,000 |
| 2023 | 2,992,000,000 | 548,000,000 | 236,000,000 |
| 2022 | 2,826,000,000 | 311,000,000 | 230,000,000 |
| 2021 | 2,594,000,000 | 236,000,000 | 226,000,000 |
| 2020 | 2,316,000,000 | 259,000,000 | 204,000,000 |
| 2019 | 2,225,000,000 | 272,000,000 | 226,000,000 |
| 2018 | 2,181,000,000 | 151,000,000 | 281,000,000 |
| 2017 | not reported | not reported | not reported |
| 2016 | not reported | not reported | not reported |
Financing and grant events (46)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-30 | Other financing | not disclosed | Sec extracted |
| 2026-06-30 | Debt financing | not disclosed | Sec extracted |
| 2026-06-30 | Debt financing | not disclosed | Sec extracted |
| 2026-06-30 | Debt financing | not disclosed | Sec extracted |
| 2024-09-30 | Private placement | not disclosed | Sec extracted |
Showing 5 of 46 events.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 24 | 2026-07-28 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2026 | 2045 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2026 | not disclosed | not disclosed |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Alexander B Olawaiye, MD | Co sponsors trial with | 1 |
Latest dated events (72)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-28 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-14 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-06-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-30 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-30 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 72 events.
Biomarker capability evidence (20)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CD274 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CSF2 | Trial collaborator | Named in trial inclusion criteria |
| CSF3 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 20 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.